# EDGAR Filing Document

**Accession Number:** 0001876431
**File Stem:** 0001628280-25-032021
**Filing Date:** 2025-6
**Character Count:** 15459
**Document Hash:** f9002b0582605cb1257a1379085e7733
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-032021.hdr.sgml**: 20250618

**ACCESSION NUMBER**: 0001628280-25-032021

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250618

**FILED AS OF DATE**: 20250618

**DATE AS OF CHANGE**: 20250618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Prenetics Global Ltd
- **CENTRAL INDEX KEY:** 0001876431
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41401
- **FILM NUMBER:** 251055290

**BUSINESS ADDRESS:**
- **STREET 1:** 7/F, K11 ATELIER, 728 KING'S ROAD
- **CITY:** QUARRY BAY
- **STATE:** K3
- **ZIP:** 000000
- **BUSINESS PHONE:** (852) 2210-7188

**MAIL ADDRESS:**
- **STREET 1:** 7/F, K11 ATELIER, 728 KING'S ROAD
- **CITY:** QUARRY BAY
- **STATE:** K3
- **ZIP:** 000000

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE<br>13a-16 OR 15d-16 UNDER<br>THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of June 2025**

**Commission File Number 001-41401** 

**Prenetics Global Limited**

---

| | |
|:---|:---|
| **11401 Granite St.**<br>**Charlotte, NC 28273**<br>**USA**  | **Unit 703-706, K11 Atelier**<br>**728 King's Road, Quarry Bay** <br>**Hong Kong** |

---

(Addresses of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F

------

**EXPLANATORY NOTE**

On June 18, 2025 - Prenetics Global Limited ("Company") issued a press release announcing its Bitcoin treasury strategy. A copy of the Press Release is furnished as Exhibit 99.1 to this Report on Form 6-K.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description of Exhibits** |
| 99.1 | <u>[Press release dated June 18, 2025](ex991preneticsbitcointreas.htm)</u> |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Prenetics Global Limited** | **Prenetics Global Limited** |
|  | By: | /s/ Lo Hoi Chun |
|  | Name: | Lo Hoi Chun |
|  | Title: | Chief Financial Officer |
| Date: June 18, 2025 |  |  |

---

## Exhibit 99.1

**Prenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to Board**

*-Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation*

*-Following strategic divestiture, Prenetics leverages strengthened $117M balance sheet to execute comprehensive Bitcoin strategy with board-approved majority allocation, institutional financing partnerships, and alpha-generating initiatives.*

Charlotte, N.C., – June 18th, 2025 - Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company, today announced it has become the first healthcare company to establish a Bitcoin treasury, completing a $20 million Bitcoin purchase of 187.42 BTC at an average price of $106,712 per Bitcoin via a Kraken custody account.

Concurrent with this groundbreaking treasury strategy, Prenetics announced the appointment of Andy Cheung, former COO of OKEx, to its Board of Directors, providing direct board-level oversight from one of the crypto industry's most experienced executives. Prenetics plans to substantially increase its Bitcoin holdings and aims to become one of the largest healthcare corporate Bitcoin holders globally.

"What excites me most is the convergence we're witnessing between healthcare innovation and blockchain technology," said Danny Yeung, CEO of Prenetics. "We're at the dawn of a new era where genomics, personalized medicine, and digital assets will intersect in ways that could revolutionize how we approach human health, longevity and wealth. To execute this vision at scale, we need substantial Bitcoin holdings – which is why, together with our institutional capital partners, we're building one of the most significant Bitcoin treasuries in healthcare."

**Andy Cheung Joins Board: Crypto Industry Titan Provides Strategic Oversight**

The appointment of Andy Cheung to the Board of Directors represents a strategic coup for Prenetics' Bitcoin treasury initiative. Mr. Cheung, former COO of OKEx (now one of the world's top-3 cryptocurrency exchanges) and current Co-Founder & CEO of both OEX and PredicXion, brings a decade of crypto exchange operations expertise, managing billions in daily trading volume. His appointment to the board provides unmatched operational guidance and governance for the company's pioneering Bitcoin treasury strategy.

"Having worked with Danny at Groupon Asia over a decade ago, I saw firsthand his ability to execute transformational strategies," commented Andy Cheung. "I'm incredibly excited about the opportunity to contribute my crypto expertise to this pioneering healthcare Bitcoin strategy. I already have numerous ideas on accumulation strategies and alpha-generating approaches that can significantly outperform simple buy-and-hold

------

tactics. This isn't about passive Bitcoin storage - we're talking about dynamic treasury management using derivatives, yield strategies, and institutional-grade trading techniques I've refined through managing billions in crypto exchange operations. The intersection of my crypto operational experience with Prenetics' healthcare innovation creates unprecedented opportunities for value creation."

**Professional Validation from Crypto Industry Leaders**

Supporting this groundbreaking strategy, Prenetics is guided by crypto industry's most influential leaders:

"We've assembled the architects of the crypto ecosystem," said Danny Yeung, CEO of Prenetics. "Andy Cheung has moved more Bitcoin in a single day than most Fortune 500 companies will ever own. Tracy Hoyos Lopez has solved regulatory puzzles that have stumped entire governments. Raphael Strauch literally brings together every major crypto decision-maker on the planet at TOKEN2049. This isn't just a team - it's the concentrated intelligence and operational firepower of the entire digital asset revolution. While other healthcare companies are still figuring out what Bitcoin is, we're building the infrastructure to dominate the intersection of health and digital wealth for the next decade. The question isn't whether we'll succeed - it's how far ahead of everyone else we'll be."

Tracy Hoyos Lopez added: "After successfully guiding President Trump's Bitcoin advocacy and seeing the regulatory environment strengthen globally, Prenetics' comprehensive Bitcoin strategy, now bolstered by their strengthened financial position, positions the company to benefit immensely from accelerating institutional adoption. Danny's ambition is large – he's not just building a Bitcoin treasury, he's architecting the future intersection of healthcare and digital assets. Their accumulation plans and alpha-generating approach represents one of the most professionally thought out Bitcoin strategies I've seen and I'm proud to support and help on this exciting journey."

Raphael Strauch commented: "Through TOKEN2049, I've witnessed the evolution of institutional crypto adoption firsthand. And I'm incredibly excited to be part of Prenetics' journey. Their comprehensive long-term Bitcoin strategy represents the kind of bold, systematic, and expertly-governed approach that separates true industry leaders from followers. Their inspiration from MicroStrategy and Metaplanet, combined with their unique healthcare focus, positions them as a definitive pioneer in what I believe will be the next wave of corporate Bitcoin adoption."

**Comprehensive Long-Term Bitcoin Strategy: Beyond Treasury Holdings**

Prenetics' Bitcoin initiative extends far beyond a simple treasury allocation, representing a comprehensive long-term digital asset strategy that includes:

------

Board-Approved Majority Balance Sheet Allocation: The Board has approved allocating the majority of Prenetics' balance sheet to Bitcoin, demonstrating unprecedented commitment to digital asset adoption within the healthcare sector.

Institutional Capital Partnership Discussions: The company is actively in discussions with leading financial institutions to develop a comprehensive long-term Bitcoin acquisition plan.

Alpha-Generating Strategies: Beyond holding Bitcoin, Prenetics will implement sophisticated alpha-generating strategies to maximize returns on its Bitcoin holdings, including yield generation, strategic lending, collateralization, and structured products.

Operational Bitcoin Integration: Prenetics will soon accept cryptocurrency payments across both of its direct-to-consumer platforms, including IM8 Health and CircleDNA, creating a seamless Bitcoin ecosystem from treasury to operations.

**Strong Business Growth Fuels Bitcoin Strategy**

Prenetics' strategic Bitcoin treasury initiative is underpinned by exceptional business performance. Management increased full-year 2025 revenue guidance to $80-100 million, demonstrating confidence in the core business trajectory, with profitability expected in Q4 2025.

The growth is notably led by IM8 Health, which achieved extraordinary success in just six months since launch:

• On track for $50M+ annual recurring revenue (ARR) run rate and growing fast

• Over 55,000 customers acquired and 4.9 million servings delivered

• Industry-leading 91% subscription rate and $109 average order value

• Global expansion to 31 countries worldwide

Prenetics operates three complementary consumer health brands: IM8 (premium health supplements), CircleDNA (leading direct-to-consumer DNA testing), and Europa (one of the largest sports nutrition distribution companies in the United States).

**Enhanced Financial Position Enables Strategic Innovation**

Prenetics' Bitcoin treasury strategy is supported by a significantly strengthened financial position:

• $117M+ Total Liquidity: Pro-forma cash, BTC and short-term assets of approximately $117 million

• $66M+ Cash Reserves: Pro-forma cash reserves of approximately $66 million

• Debt-Free Balance Sheet: Zero debt maintaining financial flexibility

------

• Strong Business Performance: Consumer health business to generate $80-100 million in revenues for FY2025

• Strategic Investment Portfolio: 35% stake in Insighta valued at $70 million based on Tencent's recent investment

**Elite Advisory Team: Trump Bitcoin Architect and TOKEN2049 Founder** 

Tracy Hoyos Lopez - Chief of Staff for Strategic Initiatives at Kraken and Board Member of the Bitcoin Advocacy Project. A former prosecutor, Tracy gained international recognition as "the woman who orange-pilled President Donald J. Trump" (a term in the crypto community meaning to educate someone about Bitcoin and convince them of its value and potential), orchestrating his historic Nashville Bitcoin conference speech and contributing millions in campaign fundraising. Tracy brings extensive legal, political, and regulatory expertise crucial for navigating corporate Bitcoin adoption.

Raphael Strauch - Founder of TOKEN2049, the world's largest crypto conference series, attracting over 40,000 attendees annually, and Founder of Alice Capital. Raphael brings unparalleled global crypto network access and institutional investment expertise, having built the premier platform for crypto industry leaders and investors worldwide.

**About Prenetics Global Limited**

Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer health. Our consumer initiative is led by IM8, a fast-growing health and wellness brand, Europa, one of the largest sports distribution companies in the USA, and CircleDNA, a leading direct-to-consumer DNA test. As the first healthcare company to establish a Bitcoin treasury with its initial $20 million Bitcoin purchase and board-approved comprehensive Bitcoin strategy, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption. The company will soon accept cryptocurrency payments across both IM8 Health and CircleDNA platforms, creating a complete Bitcoin ecosystem from treasury to operations. This includes exploring how blockchain technology can further enhance our genomics solutions, such as CircleDNA, by ensuring data integrity, privacy, and secure access to personalized health insights, while establishing new paradigms for corporate treasury management. Each of Prenetics' units synergistically enhances our global impact on health, embodying our commitment to "enhancing life through science". To learn more please visit prenetics.com and IM8health.com

**Investor Relations Contact:**<br>investors@prenetics.com<br>PRE@mzgroup.us

Angela Cheung<br>Investor Relations / Corporate Finance

------

<br>Prenetics Global Limited<br>angela.hm.cheung@prenetics.com

**Forward-Looking Statements**

****<br> This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the Company's ability to further develop and grow its business, including new products and services; its ability to execute on its new business strategy in genomics, precision oncology, and specifically, early detection for cancer; the results of case control studies and/or clinical trials; and its ability to identify and execute on M&A opportunities, especially in precision oncology. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the "Risk Factors" section of the Company's most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

<br>